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Late stage diabetic nephropathy is histologically characterized by either
diffuse or nodular expansion of the glomerular matrix. This is presumed
to represent the morphological correlate for the functional impairment
of the kidney. The exact matrix composition of the nodular glomerulo-
sclerosis lesion of end-stage diabetic nephropathy is not known. Bio-
chemical studies have provided evidence that the microfibrillar collagen
type VI is increased in diabetic nephropathy. Consequently, this
immunohistochemical study was designed to evaluate the extent and
exact morphologic location of increased collagen VI deposition at
various stages of diabetic glomerulosclerosis (GS). An irregular, some-
times spot-like staining of collagen VI was observed in diffuse GS in the
mesangial portion. The uninterrupted staining which was evident along
the glomerular basement membrane in normal glomeruli was discontin-
uous in diffusely sclerotic glomeruli. In nodular GS, the markedly
increased deposition of collagen VI appeared to be evenly distributed
throughout the entire nodular lesion. At the same time, mesangial
staining for collagen IV was reduced in nodular OS, suggesting that in
the expanded mesangial matrix collagen IV is progressively substituted
by collagen VI during the transition from diffuse to nodular GS. The
colocalization of PAS staining with collagen VI deposition in nodular
GS suggests that the typical Kimmelstiel-Wilson lesions at least in part
consist of collagen VI. Biochemical analysis confirmed the increased
collagen VI deposition in glomeruli extracted from diabetic patients
with nodular OS. Application of two antisera, recognizing primarily the
al(VI)- and a2(VI)-chains and the N-terminal part of a3(VI)-chain,
respectively, revealed no difference in staining pattern. Comparison of
the immunohistochemical results with clinical parameters of diabetic
nephropathy suggested that increasing collagen VI deposition may be
an indicator of the irreversible remodeling of the glomerular matrix to
nodular OS which is associated with functional insufficiency. Our
findings indicate striking differences of the mesangial matrix composi-
tion in diffuse and nodular GS. These observations together with earlier
results provide evidence for a "switch" in the matrix protein produc-
tion in association with the development of nodular GS in diabetic
nephropathy.
The characteristic morphological and ultrastructural changes
in patients with diabetic nephropathy are the thickening of the
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glomerular basement membrane (GBM) and the expansion of
the mesangial matrix [1—5]. Enlargement of the mesangium
occurs at the expense of the glomerular capillary luminal space
and filtration surface [6, 7]. These changes are found in about
one-third of the patients with type 1 (insulin-dependent) diabe-
tes mellitus who then progress to kidney failure, and often to
death with overt diabetic nephropathy [8]. Previous immuno-
histochemical [9—11] and biochemical [12—15] studies on the
composition of human glomerular matrix indicated a consider-
able change in the deposition of various components of the
extracellular matrix in diabetic nephropathy. Particularly, it has
been shown that morphologicaily early lesions, characterized
by a diffuse expansion of glomerular matrix, are associated with
an increased deposition of various basement membrane com-
ponents, especially that of different isoforms of collagen IV [10,
11], of laminin [9, 11] and fibronectin [9, 11]. The basement
membrane specific heparan sulfate proteoglycan (HSPG) was
shown to be markedly reduced both by biochemical [12] and
immunohistochemical analysis [11].
In contrast to the extensive analysis of these morphologically
early lesions, late stage diabetic glomerulopathy associated
with nodular glomerulosclerosis has been investigated much
less intensively. Our previous studies demonstrated a decrease
of all basement membrane components tested in late stage
noduli. The occurrence of interstitial collagen III was restricted
focally to peripheral parts of the noduli. Therefore, the compo-
sition of the typical diabetic nodular matrix (Kimmelstiel-
Wilson noduli) remained unknown. The only evidence for the
nature of the nodular composition came from PAS staining
which—although unspecific—indicates the presence of carbo-
hydrate-rich material. Recently, Mohan, Carter and Spiro [13]
provided evidence that the microfibrillar collagen VI which had
previously been morphologically shown in normal glomeruli
[16, 17] was also biochemically detectable in normal glomeruli
and present in increased amounts in those of diabetics [13]. The
authors proposed that this increased deposition may serve as an
index for glomerular matrix expansion. Preparation of the
glomerular matrix by available procedures, however, yields
material containing both GBM and mesangial matrix. There-
fore, the precise anatomical localization of collagen VI re-
mained unclear.
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Table 1. Patients studied with insulin-dependent type I and non-insulin-dependent type II diabetes mellitus, and correlation of clinical and
pathobiochernical parameters
Urinary
Patient
no.
Age!
sex
years
Type of
diabetes
Duration
of diabetes
years
Serum
creatine
mg%
Creatine protein
clearance excretion
mI/mm g/24 hr
Histol.
type of
lesion
Collag
IV
en y
VI
1 82/f II NR 1.2 110 0 DGS — —.
2 89/f II 17 1.6 120 0 DGS —+ —*
3 64/f II NR 2.5 NR NR DGS - -
4 39/rn I NR 1.8 NR NR DGS ft —* t
5 62/f I 14 1.8 NR 4.0 DGS ft -1'
6 80/f II NR 1.9 40 5.2 DGS ft —* f
7 61/f II >10 2.6 45 2.7 DGS ft —*t
8 67/rn I 17 2.2 NR 5.5 NGS , ft
9 70/rn 11(b) 22 5.4 (on hemodialysis) NGS ft
10 63/rn 11(b) 16 8.6 (on hemodialysis) NGS ft
Abbreviations are: DGS, diffuse GS; NGS, nodular US; NR, not reported. Staining intensities compared to normal renal tissue are: (—p) no
change; (t) increased; (if) strongly increased; (J1) decreased; () strongly decreased.
a Minimal DGS
sufficient clinical data, especially serum creatinine, creatinine
Fig. 1. Immunobloning of type VI collagen in guanidine extracts of
glomeruli from normal and diabetic subjects. Purified native (lane 1) or
pepsin-digested (lane 2, 5) collagen VI standard from human placenta
and glomerular extracts of normal (lane 3, 6) and diabetic subjects (lane
4, 7) were transferred to nitrocellulose sheet after reduction and
electrophoresis, and reacted with antisera against pepsin-solubilized
collagen VI (lanes 1 through 4) or the N-terminal fragment of a3(VI)-
chain (lanes 5—7). One microgram of protein was applied on lanes 1, 2
and 5, while lanes 3, 4 and 6, 7 contained 24 sg protein.
The objective of the present study was therefore to charac-
terize the regional distribution and extent of collagen VI depo-
sition in diabetic glomeruli by immunohistochemistry and com-
pare the findings with clinical parameters of diabetic nephropathy
of the respective patients. Although it was not the aim of our
study to quantitate increased glomerular collagen VI deposition
in individual diabetic subjects, we have biochemically deter-
mined collagen VI in some cases to confirm our immunohisto-
chemical findings. The data demonstrate that collagen VI rep-
resents a major matrix constituent particularly of late stage
nodular glomerulosclerosis.
Methods
Tissue
Renal tissue specimens were obtained from 21 patients with
clinically manifest diabetes mellitus. In 10 cases, additional
clearance, and urinary protein excretion were reported for
evaluation of the renal function. These data were used to
determine whether a correlation between glomerular structure
and renal function exists (Table 1). Control tissue comprised
eight kidney specimens obtained at autopsy from previously
healthy accident victims.
For the histologic analysis, tissues were fixed in 4 to 8%
buffered formalin for 24 hours followed by routine processing
and embedding into paraffin. From each block 2 pm serial
sections were cut and placed on silanized slides.
Antibodies
Anti-human collagen IV and anti-mouse laminin antibodies
were purchased from Eurodiagnostics (Leiden, NL). Anti-
human fibronectin was from DAKO (Hamburg, Germany).
Antisera to basement membrane associated heparan sulfate
proteoglycan (HSPG) were prepared and characterized as pre-
viously described [181. Antibodies against interstitial collagens
I and III were prepared according to established procedures
[19]. Decorin antiserum was purchased from Biomol (Hamburg,
Germany). Antisera against the microfibrillar collagen VI were
obtained by immunization of rabbits with pepsin solubilized
collagen VI [17]. In addition, rabbit antisera were prepared
against recombinant N- and C-terminal peptides of collagen
a3(VI)-chain N9-N2 [20] and CS (unpublished data). The spec-
ificity of the antisera was tested by enzyme immunoassay [17].
Immunohistochemical staining
Formalin fixed and paraffin embedded tissue sections were
deparaffinized and incubated with 0.4% pepsin as described for
the immunohistochemical enhancement of staining of the base-
ment membrane components [21]. The sections were first
incubated with a specific primary antiserum. Subsequently,
avidin-biotin-complexed anti-rabbit antibodies (Vector, Burlin-
game, Vermont, USA) were used as secondary antibodies [22].
The avidin-biotin-complexes of the secondary antibodies were
visualized with aminoethylcarbazole (Sigma, Deisenhofen, Ger-
many). Additionally, the alkaline phosphatase-anti-alkaline
phosphatase (APAAP-) method [23] was used in few instances
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for the confirmation of the staining results. All sections were
evaluated by routine light microscopy.
Western blot analysis of GBM of diabetic subjects
GBM were prepared from human kidneys of diabetic subjects
with nodular glomeruloscierosis as described previously [13,
14]. GBM were then extracted with 4 M guanidine HC1, 0.5 M
sodium phosphate at pH 7, containing 20 mtvi dithiothreitol in
the presence of protease inhibitors as previously described [13,
18]. The proteins were resolved by sodium dodecyl sulfate on
polyacrylamide gel electrophoresis (SDS-PAGE) [24] using a
linear 4 to 15% gradient gel. After transferring the resolved
proteins to nitrocellulose sheets collagen VI was immunologi-
cally detected using specific antisera against pepsin-solubilized
collagen VI, N9-N2 and CS followed by a goat anti-rabbit IgG
horseradish peroxidase conjugate. The chemoluminescence
system (ECL) of Amersham (Braunschweig, Germany) was
used for visualization of bound antibody.
Biochemical quantjflcation of collagen VI in normal and
diabetic glomerular extracts
Normal and diabetic glomerular extracts were analyzed for
collagen al(VI), a2(VI) and a3(VI) chains, respectively, using
an enzyme immunoassay [13]. Serial dilutions of sample and
standard solutions were prepared to obtain decreasing reactiv-
ity and enzyme immunoassay was performed with both anti-
sera. Comparison with standard curves yielded the values for
collagen VI content. Basement membrane-associated heparan
sulfate proteoglycan was determined as described recently [25].
Results
Identjfication of collagen VI in extracts of human glomeruli
obtained from normal and diabetic subjects
Antisera against pepsin-solubilized collagen VI which con-
sists mainly of the triplehelical domain [17] and against the
N-terminal globular domain N9-N2 of the a3(VI)-chain [20]
were initially used in immunoblotting. The first antiserum
reacted primarily with a poorly resolved 140 kDa double band in
native collagen VI (Fig. 1, lane 1), and 60 and 70 kDa bands in
pepsin-solubilized collagen VI (Fig. 1, lane 2), which are known
to correspond to the al(VI)- and a2(VI)-chains [25]. Only very
faint reactions were observed with a 200 kDa (native collagen
VI) and 50 kDa (pepsin-solubilized collagen VI) band that
comprises the a3(VI)-chains [25]. This indicates a preferential
specificity of this antiserum for al(VI)- and a2(VI)-chains
epitopes. Smaller stained bands are also present in native
collagen VI, which we believe are degradation products of these
chains because their intensity increases during storage. With
the same antiserum a faint 140 kDa band could be detected in
guanidine extracts of normal glomeruli (Fig. 1, lane 3) and was
more prominent in extracts of diabetic glomeruli (Fig. 1, lane 4).
The antiserum against recombinant N9-N2 was used to detect
a3(VI)-chain epitopes since it reacted in enzyme immunoassays
strongly with N9-N2 and much weaker with recombinant
al(VI)- and a2(VI)-chains (data not shown), and a3(VI)-chains
have so far not been demonstrated in glomerular extracts (lane
5) [13]. Immunoblots detected a weak 200 kDa band in extracts
of normal glomeruli (Fig. 1, lane 6) which was replaced by a
similar, more intensely stained double band in the diabetic
glomerular extracts (Fig. 1, lane 7). In addition, a few smaller,
presumably degraded bands could be also detected. No reaction
could be observed with the antiserum against C-terminal CS
epitopes of a3(VI)-chain in the glomerular extracts and in native
collagen VI (data not shown), suggesting that the epitopes may
either be proteolytically processed or lost during extraction.
Quantitative determination with enzyme immunoassay showed
increased collagen VI content and decreased HSPG content in
glomerular extract from normal and diabetic subjects with
nodular GS. Case #9 (Table 1) which was representative for
this group (see also immunoblot Fig. 1) had 62 pg collagen VI
and 8 jxg HSPG/mg protein of glomerular extract, while the
normal control shown in Figure 1 had 29 g collagen VI and 24
jxg HSPG/mg protein, respectively. Furthermore, application of
the antiserum recognizing specifically the a3(VI)-chain revealed
no change in the a1/2:a3 ratio in nodular GS. In general, the
data confirm recent results demonstrating a strong increase in
the deposition of collagen VI [13], which is composed of al(VI),
a2(VI) and a3(VI)-chains in diabetic glomeruli.
Immunohistochemistry of normal glomeruli
Unaltered glomeruli of healthy patients demonstrated a dis-
tinct collagen VI staining of the mesangial matrix tuft, as well as
a faint and linear staining along the GBM region (Fig. 2d). By
comparison, a similar staining pattern in normal glomeruli was
found for the basement membrane components collagen IV
(Fig. 2a), laminin and collagen V. HSPG was localized in the
glomerular basement membrane and in the mesangial matrix
(Fig. 2b). Fibronectin was deposited in mesangial areas. Along
the GBM it was present only focally. No significant staining for
the interstitial collagens III (Fig. 2c) and I (data not shown) was
observed in the glomerular extracellular matrix.
A comparison of antisera against different epitopes showed
identical staining patterns with those raised against pepsin-
solubilized collagen VI and the N9-N2 structure, while no
staining was observed with the antiserum against the C-terminal
a3(VI)-chain epitopes. Similar observations were made for the
diabetic tissue samples (see below) and are in agreement with
the immunoblotting data.
Diffuse glomeruloscierosis
As previously shown [11] the diffuse enlargement of the
glomerular matrix is mainly associated with an increase in
staining for collagen IV (Fig. 3e), laminin, fibronectin and
collagen V, while staining for the BM-HSPG was markedly
Fig. 2. Immunohjstochemical distribution of extracellular matrix components in the normal human glomerulum. (A) Collagen IV is found along
the glomerular basement membrane (-.-*), in the mesangial matrix as well as in the basement membrane of Bowman's capsule and the tubuli (')
in almost equal amounts. (B) HSPG is located in the GBM (—*) and the mesangial matrix with a much higher staining intensity than in the BM of
Bowman's capsule and the tubuli (). (C) Normal glomeruli lack collagen III completely, while this collagen type is found in the surrounding
interstitial matrix. (D) Collagen VI normally occurs in the mesangial matrix of the glomerulum and in the interstitium of the surrounding
periglomerular matrix, and it is seen faintly along the GBM (—+). (A—D: original magnification X 400)
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Fig. 3. Distributionofcollagen VI (andIV) in d(ffuse diabetic glomerulosclerosis. (A) In the PAS staining the expansion of the mesangial matrix
is seen (') showing an intense positive reaction for glycoproteins. The GBM is well recognizable (—') (Case #5 in Table 1). (B) In a serial section,
collagen VI is mainly found in the periglomerular matrix (k). In the glomeruli, it is seen focally in small peripheral glomerular tufts, while the
enlarged mesangium reacts only weakly with the antibody (). Note also the focal reduction of staining along the GBM (—'). (C) In another
example (Case #7 in Table 1) almost identical findings are seen in the PAS staining with enhanced mesangial staining (') and well demarcated
GBMs (—'). Here, in the periphery, a "beginning" nodular formation is seen (').((D) The corresponding staining for collagen VI in a serial
section again shows faint and only focal reaction in the mesangium ('), increased staining in the area of "beginning" nodular formation ()and
faint to absent reaction along the GBM (—*). (E) Collagen IV is extensively increased in the diffusely enlarged mesangium (') and in the GBM (—*)
(same patient as in C and D, but no serial section). (F) Detailed view of collagen VI in a diffusely sclerotic glomerulum (Case #4 in Table 1). Note
the only faintly positive, (often absent) and irregular staining in the mesangium (') and the reduced staining along the GBM (—p). The
periglomerular interstitial matrix reacts positively (ø). (A—D: original magnification x 400; E: x 300; F: x 600)
decreased. In these altered glomeruli a focal, irregular and only
sometimes spot-like and slightly increased staining for collagen
VI was observed in the mesangial portion of the glomerulus
(Fig. 3 b, d). In contrast, the staining along the glomerular
basement membrane, seen in unaltered, normal glomeruli was
not continuous in most areas of diffusely sclerotic glomeruli
(Fig. 3 b, d). A side-by-side comparison of the collagen VI
staining pattern (Fig. 4 b, d) with that of the PAS staining (Fig.
3 a, c) revealed only a partial overlap of both stainings.
Nodular glomerulosclerosis
The immunohistochemical investigation of late stage nodular
glomeruloscierosis demonstrated a marked reduction in staining
for all basement membrane components tested, particularly for
collagen IV (Fig. 4d), laminin, HSPG and fibronectin. Some
residual staining was observed in peripheral parts of glomerular
capillary loops present at the periphery of the noduli (Fig. 4d).
In addition, these noduli remained unstained for collagen I,
while peripheral, crescent-shaped areas of the noduli stained
positively for collagen III (not shown). Only faint staining for
collagen V was seen in central regions. In contrast, all noduli
demonstrated an intense staining reaction for collagen VI in a
rather homogenous fashion (Fig. 4 b, c, e). The staining pattern
of collagen VI was overlapping with that of the PAS staining
(Fig. 4a). In no case staining for the proteoglycan decorin was
observed in expanded mesangial matrix or in noduli of GS (data
not shown).
Comparison of immunohistochemical findings and clinical
parameters
In 10 cases in our study group sufficient additional clinical
data were reported for the evaluation of the renal function. The
patient-by-patient results are depicted in Table 1. A correlation
of clinically evaluated renal function and immunohistochemical
composition of the glomeruli revealed a marked increase in the
mesangial collagen VI content in three patients. This collagen
VI deposition was associated with a severe renal function
impairment and renal insufficiency, respectively. In the other
cases no significant correlation existed between renal function
impairment and collagen VI staining.
Discussion
Collagen VI is an ubiquitous protein present in many types of
extracellular matrices. Its monomer consists of three distinct
polypeptide chains, al(VI), a2(VI) and a3(VI) [26—31]. Tetram-
ers are assembled intracellularly and represent the basic units of
long beaded fibrils. Collagen VI is a major component of
microfibrils observed in situ and in cell cultures. It possesses
distinct cell binding properties [32, 33]. Hatamochi et a! [34]
have shown that the expression of collagen VI is regulated
differently than that of collagen I, III and fibronectin. This study
also suggested that collagen VI may be a requirement to provide
an appropriate extracellular environment for cultured fibro-
blasts to arrest proliferation.
Our present study demonstrates that collagen VI is a major
component in the expanded mesangial matrix of nodular OS.
The ability of our antisera to specifically detect collagen VI in
glomerular extracts from diabetic kidneys was shown by immu-
noblotting. A comparison of immunoblots of guanidine extracts
obtained from diabetic and non-diabetic subjects together with
the quantitative measurements confirmed increased amounts of
collagen VI in diabetic GS reported recently [13]. Our data also
demonstrate that the normal and diabetic extracts contained
al(VI), a2(VI) and a3(VI)-chains and that the ratio of al/a2 vs.
a3-chains is unchanged in nodular GS. We applied both antisera
to characterize the tissue distribution of collagen VI by immu-
nohistochemistry and compared the pattern with those of other
extracellular matrix components (Table 2). In diffusely glomer-
uloscierotic noduli only focal deposition of collagen VI was
observed, indicating a restricted synthesis by some mesangial
cells. The residual matrix expansion was obviously due to the
deposition of basement membrane components which may also
be produced by cell types other than mesangial cells. This is
corroborated by the findings that the normally faint deposition
of collagen VI along the glomerular basement membrane is
reduced or even focally absent in diffusely sclerotic glomeruli.
This would also implicate that epithelial and endothelial cells
apparently are not involved in the increased collagen VI pro-
duction in diabetic glomerulopathy. Our results indicate that
collagen VI synthesis is differently affected in different cell
types in diabetes.
A comparison of the stage of glomerulopathy with immuno-
histochemical staining of extracellular matrix components sug-
gests that collagen IV is a marker for diffuse GS. It appears that
in late diffuse GS, the decrease of collagen IV is attenuated by
the gradual increase of collagen VI in the expanded mesangial
matrix. Therefore, collagen VI may serve as a marker for
nodular GS. Furthermore, the substitution of a basement mem-
brane component by the microfibrillar collagen VI may indicate
an irreversibly deranged remodeling of the glomerular struc-
ture.
In an additional attempt to clarify the role of the altered GBM
composition in diabetic nephropathy, we were able to compare
clinical parameters of renal functions of 10 patients with immu-
nohistologic results (Table 1). Although we are aware that it is
difficult to correlate renal functional parameters to our semi-
quantitative immunohistochemical staining patterns, we pro-
vide evidence that those patients with severe alteration of the
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Fig. 4. Localization of collagen VI (and IV) in nodular glomerulosclerosis. (A) The PAS staining shows an intense reaction of the expanded
mesangial matrix () and positive reaction of the GBM (—) and the basement membrane of Bowman's capsule and tubuli (Case #9 in Table 1).
(B) In a serial section the staining pattern for collagen VI is widely coincidental with the glomerular PAS staining with intense mesangial staining
('). Note the lack of reaction along the GBM (—f). (C) Another example of collagen VI staining in nodular glomerulosclerosis (Case #9 in Table
1) also shows positive reaction within the noduli (), while "residual" diffusely sclerotic areas () react only weakly. (D) Collagen IV in the same
case, in a semiserial section as C, is present in the diffusely sclerotic areas of the glomerulum ('), but is only faintly seen in the nodular matrix
('). (Case #9 in Table 1). (E) A detailed view of some noduli (Case #8 in Table 1) demonstrates the positive collagen VI staining pattern of the
noduli ('), while the GBM reacts only very faintly to hardly at all (—i.). (A—D: original magnification X 400; E: >( 600).
Table 2. Changes of glomerular matrix composition in different
stages of diabetic glomerulosclerosis (GS) [11]
GBM
diffuse OS
mesangium GBM
nodular GS
mesangium
Collagen VI C (focally) central tI
(evenly)
Collagen IV, FN LN C C C
HSPG
Collagen I — — — —
Collagen HI — (+) (focally) — peripheral +
central —
Collagen V C C C peripheral C
Abbreviations are: LN, laminin; FN, fibronectin; HSPG, heparan
sulfate proteoglycan. Symbols are: (1') increased; (l) decreased; (+)
present; (—) not detectable.
kidney function show marked increase in mesangial collagen VI
staining. However, no good correlation of the collagen VI
staining could be found in early or late diffuse GS. Although the
pattern of PAS staining and of collagen VI localization seems to
be strongly overlapping in nodular lesions, whether collagen VI
is the only component of the noduli remains open. A positive
PAS staining of collagen VI is known [291, but it is also
conceivable that collagen VI may provide binding sites for
carbohydrate-rich proteoglycans. It has been reported that the
small proteoglycan decorin [35], as well as hyaluronan [20, 36]
firmly associate with collagen VI. However, our immunohisto-
chemical studies with an antiserum recognizing the core protein
of decorin showed no staining in diffuse or nodular OS, and no
chondroitin sulfate has been so far detected in diabetic GS (D.
Woodrow, personal communication). As basement membrane-
associated heparan sulfate proteoglycan is decreased in diabetic
nephropathy [11, 13, 14], this proteoglycan may also not
account for increased PAS staining.
The non-enzymatic glycation of glomerular extracellular ma-
trix is rather low in diabetes despite elevated levels in other
tissues [37, 38] and therefore not a good candidate for explain-
ing the high PAS reactivity. A recent study on diabetic cardio-
myopathy of rats has demonstrated a similar codistribution of
PAS positive material and collagen VI in the heart extracellular
matrix [39]. This, together with our observations, suggests that
the massive collagen VI deposits represent at least a large
portion of the PAS staining material in these sclerotic lesions.
Another important feature of nodular glomerulosclerosis is
the relatively low number of cells present in the matrix. Since it
has been suggested that collagen VI may contribute to prolifer-
ative arrest in vitro [34], it is possible that an increase in
collagen VI is associated with a decrease in mesangial cell
proliferation in vivo.
In summary, our findings of increased collagen VI deposition,
particularly in late stage nodular glomerulosclerotic lesions,
further our understanding of the structural abnormalities of
diabetic glomerulopathy and its possible underlying molecular
mechanisms. Although the contribution of collagen VI deposi-
tion to the overall matrix expansion seems to be of only minor
importance in diffuse glomerulosclerosis, it appears to play a
dominant role in the nodular form of glomerulopathy. This
supports the suggestion that these noduli are predominantly of
mesangial origin. Previously, it has been reported that collagen
I may be an integral part of the nodular GS [40]. This assump-
tion, however, has not been confirmed by studies of the
authors' laboratory [11] nor by others [9, 41]. In addition, the
lack of positive staining for interstitial collagen III [11] in
central parts of these noduli further supports the aforemen-
tioned notion. Our data together with earlier reports suggest
that collagen IV distribution may serve as a marker for diffuse
GS, while the mesangial localization of collagen VI represents
an index of nodular GS.
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